Company Description
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds.
The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Jonathan Lim |
Contact Details
Address: 3115 Merryfield Row, Suite 300 San Diego, California 92121 United States | |
| Phone | 858 465 6511 |
| Website | erasca.com |
Stock Details
| Ticker Symbol | ERAS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1761918 |
| CUSIP Number | 29479A108 |
| ISIN Number | US29479A1088 |
| Employer ID | 83-1217027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of Research and Development, Scientific Advisory Board Member and Director |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer |
| Alison Tjosvold Milhous | Senior Vice President of Accounting |
| Dr. Robert Shoemaker Ph.D. | Chief Scientific Officer |
| Ebun S. Garner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer |
| Minli Xie Ph.D. | Senior Vice President of Pharmaceutical Development and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 21, 2026 | 144 | Filing |
| Jul 14, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 424B5 | Filing |
| Jul 13, 2026 | 424B5 | Filing |
| Jul 13, 2026 | 8-K | Current Report |
| Jul 13, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 144 | Filing |
| May 15, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |